BIAF:NASDAQ, bioAffinity Technologies, Inc.
BIAF stock overview
bioAffinity Technologies, Inc. (BIAF:NASDAQ) closed at $3.57 on October 21, 2026,
down 2.46% on the day.
The stock trades 95.6% below its 52-week high of $80.70
and 10.5% above its 52-week low of $3.23.
bioAffinity Technologies, Inc. is part of the Health Care sector.
Key figures
- Price
- $3.57
- Day change
- -2.46%
- Volume
- 61,885
- Average volume
- 3,708,353
- Market cap
- 4M+
- 52-week range
- $3.23 – $80.70
- 50-day average
- $6.69
- 200-day average
- $19.90
Price action over the past year
In 251 trading sessions since October 21, 2025, BIAF closed higher on 92 days (37%).
Its best day was March 13, 2026 (+98.13%) and its worst was September 8, 2026 (-41.52%).
The stock moved 10% or more in a single session 53 times.
It opened at least 5% above the previous day's high 12 times.
Recent signals
BIAF news
-
Oct 15, 2026:
bioAffinity Technologies to Present New Perspectives on CyPath Lungs Use for Cancer Risk Assessment at CHEST 2026
-
Oct 15, 2026:
bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
-
Oct 13, 2026:
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
-
Oct 9, 2026:
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Oct 9, 2026:
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Oct 8, 2026:
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Oct 8, 2026:
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Oct 8, 2026:
bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
About bioAffinity Technologies, Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Similar stocks
Find more stocks like BIAF with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.